Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14MQE | ISIN: IL0011284614 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
KADIMASTEM LTD Chart 1 Jahr
5-Tage-Chart
KADIMASTEM LTD 5-Tage-Chart

Aktuelle News zur KADIMASTEM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.11.NLS Pharmaceutics and Kadimastem stocks soar following merger agreement1
04.11.NLS Pharmaceutics und Kadimastem fusionieren in Biotech-Deal1
04.11.NLS Pharmaceutics stock rallies 48% on merger agreement with cell therapy developer Kadimastem3
KADIMASTEM Aktie jetzt für 0€ handeln
04.11.NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement257ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA") ("Kadimastem")...
► Artikel lesen
29.07.Kadimastem To Become Subsidiary Of NLS; Kadimastem Shareholders To Hold 85% Of Merged Company Shares-
29.07.NLS Pharmaceutics announces binding term sheet to merge with Kadimastem2
29.07.NLS Pharmaceutics AG: NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge317The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy...
► Artikel lesen
18.07.Pluri's CDMO to Manufacture Kadimastem's Cell Therapy Candidates2
18.07.Pluri Inc.: Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates678HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global...
► Artikel lesen
28.05.IM Cannabis Corp (3): IM Cannabis terminates term sheet with Kadimastem2
28.05.IM Cannabis Corp.: IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market317With Germany delivering accelerated growth after legalization, IMC is keeping all options open to maximize shareholder value TORONTO and GLIL YAM, Israel, May 28, 2024 /PRNewswire/ --...
► Artikel lesen
28.02.IM Cannabis Corp.: IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company470Not for distribution to United States newswire services or for dissemination in the United States TORONTO and GLIL YAM, Israel, Feb. 28, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE:...
► Artikel lesen
12 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1